Cortisporin Otic (hydrocortisone/neomycin/polymyxin otic) dosing, indications, interactions, adverse effects, and more

Sections

Sections hydrocortisone/neomycin/polymyxin otic
Dosing & Uses
Adverse Effects
Warnings
Pregnancy
Pharmacology
Images
Patient Handout
Formulary

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

hydrocortisone/neomycin/polymyxin otic

otic solution/suspension

10mg (1%)/3.5mg (0.35%)/10000units/10mL

Superficial Bacterial Infections of External Auditory Canal

4 drops in ear q6-8hr; not to exceed 10 days

Bacterial Infections of Mastoidectomy & Fenestration Cavities

4 drops in ear q6-8hr; not to exceed 10 days

Dosage Forms & Strengths

hydrocortisone/neomycin/polymyxin otic

solution

10mg (1%)/3.5mg (0.35%)/10000units/10mL

Superficial Bacterial Infections of External Auditory Canal

3 drops in ear q6-8hr; not to exceed 10 days

Bacterial Infections of Mastoidectomy & Fenestration Cavities

3 drops in ear q6-8hr; not to exceed 10 days

Frequency Not Defined

Hypersensitivity

Itching

Redness

Skin rash

Swelling

Contraindications

Hypersensitivity to any agent

Cutaneous viral infection of the external auditory canal (solution only); patients with herpes simplex, vaccinia, and varicella infections

Cautions

Neomycin sensitization, including itching, reddening, edema, and failure to heal may occur; discontinue therapy if it occurs

Solution does not penetrate quite as well as suspension does

Systemic absorption of topical corticosteroids may cause hypothalamic-pituitary-adrenal axis suppression, which may lead to adrenal crisis, especially in children and in patients receiving large doses for prolonged periods

Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection, and may also prolong or exacerbate viral infections

Development of Kaposi sarcoma associated with prolonged treatment with corticosteroids; discontinue therapy if it occurs

Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, including destruction of hair cells in the organ of Corti; risk of ototoxicity is greater with prolonged use

Percutaneous absorption of topical corticosteroids may occur, which may cause manifestations of hyperglycemia, Cushing syndrome, or glycosuria; use of occlusive dressings, application fo denuded skin, or application to large surface areas may increase risk of absorption

Pregnancy & Lactation

Pregnancy category: C

Lactation: Unknown whether drug is excreted in milk; use with caution

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Mechanism of Action

Hydrocortisone: Suppresses inflammatory response

Neomycin: Inhibits protein synthesis

Polymyxin: Bactericidal; active against gram-negative bacteria; disrupts bacterial cytoplasmic membrane structure and alters membrane permeability to allow leakage of intracellular contents

Absorption

Agent is absorbed if eardrum is perforated or tissue damage is present

Images

No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Create Your List of Plans

Adding plans allows you to:

View the formulary and any restrictions for each plan.
Manage and view all your plans together – even plans in different states.
Compare formulary status to other drugs in the same class.
Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

View explanations for tiers and restrictions

Tier	Description
1	This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2	This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6	This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC	NOT COVERED – Drugs that are not covered by the plan.

Code	Definition
PA	Prior Authorization Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL	Quantity Limits Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST	Step Therapy Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR	Other Restrictions Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]